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Aim: The aim of this paper is to determine clinical factors related to hostility and disturbing and aggressive behav-
iour and to examine the effect of medication on these behaviours in FEP.
Methods: Data from phase I and II of the OPTiMiSE trial are used. Outcomemeasures are the hostility item of the
Positive and Negative Syndrome Scale (PANSS P7) and the disturbing and aggressive behaviour domain of the
Personal and Social Performance scale (PSP-D).
Results: Moderate, severe or extreme hostility (PANSS P7 > 3) was present in 42 patients (9.4%). The PANSS P7
and PSP-D were low to moderate but significantly associated with the selected PANSS items: delusions, halluci-
natory behaviour, excitement, tension, uncooperativeness, unusual thought content, impulsivity, and lack of
judgement and insight. In a subsample of 185 patients (41.5%) with baseline PANSS P7 > 1, the PANSS P7 and
PSP-D scores improved in the first 4 weeks of amisulpride treatment. This effect remained significant after con-
trolling for baseline positive symptoms (PANSS P1-P6). No significant differences were found between
olanzapine and amisulpride in the second phase of the trial.
Conclusion: Clinical risk factors such as poor impulse control, uncooperativeness and excitement could help clini-
cians in detecting and treating hostile and aggressive behaviour in FEP. Amisulpride could be an effective antipsy-
chotic choice in the treatment of FEP patients who express hostile or aggressive behaviour. Future research is
needed to compare the effects of amisulpride and olanzapine on hostility in FEP during the first weeks of
treatment.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
A considerable proportion of patients with first episode psychosis
(FEP) are involved in aggressive incidents. Studies estimate that around
30% of patients commit at least one violent act during their first psy-
chotic episode (Large and Nielssen, 2011;Winsper et al., 2013). Aggres-
sion often leads to a number of negative consequences for the patients
as well as their immediate social network, health care workers and
the public, such as prolonged hospitalisation or social isolation (Lahera
et al., 2015; Volavka, 2008).
For clinicians, it is essential to have some knowledge of the factors that
are associated with hostile or aggressive behaviour, as this enables risk
assessment and treatment planning. Clinical risk factors for hostile or ag-
gressive behaviour in psychotic disorders in general include previous
violence, symptoms ofmania, substance abuse, treatment non adherence,
excitement, impulsivity, lack of insight and positive symptoms
(Arango, 2000; Arango et al., 1999; Bobes et al., 2009; Faay and van
Os, 2020; Fazel et al., 2009; Volavka et al., 2016; Witt et al., 2013).
Specifically for FEP, a meta-analysis identified risk factors for any
type of violence, which included younger age, male sex, substance
Schizophrenia Research xxx (xxxx) xxx
⁎ Corresponding author at: UMC Utrecht, internal post no A01.126. Heidelberglaan 100,
P.O. Box 85500, 3508 GA Utrecht, the Netherlands.
E-mail address: m.d.m.faay@umcutrecht.nl (M.D.M. Faay).
SCHRES-08943; No of Pages 8
https://doi.org/10.1016/j.schres.2020.08.021
0920-9964/© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Contents lists available at ScienceDirect
Schizophrenia Research
j ourna l homepage: www.e lsev ie r .com/ locate /schres
Please cite this article as:M.D.M. Faay, G.C.M. van Baal, C. Arango, et al., Hostility and aggressive behaviour in first episode psychosis: Results from
the OPTiMiSE trial, Schizophrenia Research, https://doi.org/10.1016/j.schres.2020.08.021
Downloaded for Anonymous User (n/a) at ClinicalKey Global Guest Users from ClinicalKey.com by Elsevier on September 28, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
abuse, manic symptoms, lower level of education and longer dura-
tion of untreated psychosis (Large and Nielssen, 2011). While posi-
tive symptoms are a risk factor for aggressive behaviour in more
chronic psychotic disorders, the findings within FEP populations
are inconsistent. In contrast to meta-analytic data (Large and
Nielssen, 2011), a 10-year follow-up study of FEP found higher pos-
itive symptom scores in patients with violent behaviour (Langeveld
et al., 2014). More specifically, certain positive symptoms, such as
delusions and uncommon beliefs were associated with violence in
FEP (Coid et al., 2013) but a recent study in an ultra-high-risk sample
found no significant relation between delusions, unusual thought
content, hallucinations and violent behaviour (Brucato et al., 2019).
Next to positive symptoms, clinical risk factors that are observed
from patients' behaviour could be important for risk management.
Impulsivity is associated with violent behaviour in early psychosis
(Moulin et al., 2018a, 2018b). In patients with more chronic psy-
chotic disorders, uncooperativeness and excitement were related
to hostile and aggressive behaviour next to impulsiveness (Faay
and van Os, 2020). However, as far as we are aware, there are no
studies examining the association between symptoms such as
uncooperativeness, excitement and tension with aggressive behav-
iour in FEP.
Although violence, aggression and hostility are different, hostile be-
haviour can be seen as a risk factor for violent or aggressive acts since
this behaviour is often observed prior to incidents (Large and Nielssen,
2011; Witt et al., 2013). Moreover, since most major studies do not in-
clude a separate measure of violence or aggression, the hostility item
of the Positive and Negative Syndrome Scale (PANSS P7 (Kay et al.,
1987)) is often used as a proxy to give an indication of the level of ag-
gressive behaviour.
Some randomized trials presented post-hoc analysis of the PANSS
hostility item. The European First Episode Schizophrenia Trial (EUFEST)
compared five antipsychotic drugs in 498 patients with first episode
schizophrenia, schizoaffective disorder or schizophreniform disorder
in terms of efficacy and tolerability. In a subset of 302 patients with at
least minimal hostility (>1) at baseline, olanzapine was superior to
other antipsychotics in reducing hostility (Volavka et al., 2011). A simi-
lar result was found in the Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE) study including 1493 patientswith schizophrenia.
Post-hoc analyses of this study found olanzapine to be significantly su-
perior in reducing hostility compared with perphenazine, quetiapine,
ziprasidone and risperidone (Volavka et al., 2014). A recent meta-
analysis, including these trials, compared the effect of antipsychotics
on hostility in 18 randomized studies. A small but significant effect
was found for second-generation as compared to first-generation anti-
psychotics (Faay et al., 2018). Especially clozapine was superior, in
line with previous studies (Frogley et al., 2012; Glazer and Dickson,
1998; Spivak et al., 1997). Current clinical guidelines recommend cloza-
pine for patients who do not respond to two adequate trials with differ-
ent antipsychotics (Warnez and Alessi-Severini, 2014). Thus, FEP
patients can only start with clozapine after several weeks of treatment.
Evidence considering the effectiveness of other second-generation anti-
psychotics on hostile and aggressive behaviour in the first weeks of
treatment is therefore needed.
The present paper focuses on the PANSS P7 hostility item and the
PSP-D disturbing and aggressive behaviour domain in the Optimization
of Treatment and Management of Schizophrenia in Europe (OPTiMiSE)
trial. We aim to determine clinical factors related to hostility and
disturbing and aggressive behaviour, and to examine the effect of med-
ication on these behaviours in FEP patients. To examine the effect of
medication, there is a two-fold aim: 1) to describe the short-term effect
of amisulpride on hostility and disturbing and aggressive behaviour and
2) to compare the effect of continuation of amisulpride versus switching
to olanzapine on hostility and disturbing and aggressive behaviour in




The rationale anddesign of theOPTiMiSE trial is described elsewhere
(Leucht et al., 2015). A total of 481 patients with first episode schizo-
phrenia, schizophreniform or schizoaffective disorder were included
in 27 sites across European countries and Israel. In phase I, patients re-
ceived open label amisulpride (200–800 mg/d). Patients who were
not in remission after 4 weeks continued in phase II of the trial and
were randomized to 6 weeks double blind treatment with either a con-
tinuation of amisulpride or a switch to olanzapine (5–20mg/d). If these
patients still not reached remission criteria at week 10, they entered
phase III where they received 12-weeks open label clozapine
(100–900 mg/d). Dosing was flexible in all three phases of the trial.
For the current analysis, data from phase I and II are used. Each country
obtained regulatory approval. All participants provided written in-
formed consent. A data safety monitoring board oversaw the study.
2.2. Measures
The Positive And Negative Syndrome Scale (PANSS (Kay et al.,
1987)), was used to assess the severity of clinical symptoms associated
with psychosis. All 30 PANSS items are scored from absent (1) to severe
impairment (7), resulting in a total score between 30 and 210. The pri-
mary outcome measure for the current analysis is the P7 hostility item,
an item on the positive subscale. Hostility is defined as “verbal and non-
verbal expressions of anger and resentment, including sarcasm, passive-
aggressive behaviour, verbal abuse and assaultiveness” (Kay et al.,
1987). The score is based on interpersonal behaviour during the inter-
view and reports by primary care workers or family during the past
week. A score of 1 indicates absent hostility, a score of 2 indicates min-
imal presence of hostility (“questionable pathology”), 3 is labelled as
“mild”, 4 is “moderate”, 5 indicates “moderate-severe”, 6 is “severe”
and a score of 7 indicates “extreme”, including marked anger, resulting
in physical assault towards others.
Next to the PANSS, the Personal and Social Performance Scale (PSP
(Morosini et al., 2000) was used. The PSP consists of four main domains
of functioning: A) social useful activities, B) personal and social relation-
ships, C) self-care and D) disturbing and aggressive behaviour. All do-
mains are scored on a 6-point scale which has a specific description of
the degrees of severity for the “disturbing and aggressive behavior” do-
main. This domain is based on behaviour during the past month and
scored from absent (1) to very severe (6), indicating “frequent aggres-
sive acts, aimed at, or likely to cause severe injuries”.
For the analysis of clinical factors associated with hostility, we se-
lected seven PANSS items to see if these are related to PANSS P7 and
PSP-D. We included the four PANSS items that are in the Excitement
Component (PANSS-EC), along with hostility: P4 excitement, G4 ten-
sion, G8 uncooperativeness and G14 poor impulse control (Montoya
et al., 2011). Impulsivity was associated with violence in FEP (Moulin
et al., 2018b) and more chronic populations (Faay and van Os, 2020),
but for excitement, tension and uncooperativeness, there is lacking ev-
idence in a population of FEP. Next to these items, we wanted to exam-
ine whether delusions and hallucinations are associated with hostility
or aggression because of the contrasting results from previous studies
(Brucato et al., 2019; Coid et al., 2013; Langeveld et al., 2014; Large
and Nielssen, 2011). We therefore included P1 delusions, P3 hallucina-
tory behaviour, and G9 unusual thought content, as this last item is as-
sociated with the first two.
Other measures used to describe the current sample include demo-
graphic data, type of care, duration of current psychosis, use of antipsy-
chotics before inclusion to the trial and Clinical Global Impression (CGI
(Guy, 1976)). Diagnosiswasmeasuredwith theMini International Neu-
ropsychiatric Interview Plus (M.I.N.I. Plus (Sheehan et al., 1998)). All
questionnaires and assessments were conducted by members of the
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local study team who were trained in the procedures and question-
naires. For administration of the PANSS, a standardised training was de-
veloped that included examination.
2.3. Statistical procedures
2.3.1. Clinical factors
To assess the clinical factors related to hostility (PANSS P7) and
disturbing and aggressive behaviour (PSP-D) in a cross-sectional fash-
ion, baseline values from the intention-to-treat samplewere used to cal-
culate Spearman's rank-order correlation (rs). In general, correlation
coefficients of 0.00 to 0.30 are considered negligible, 0.30 to 0.50 low,
0.50 to 0.70 moderate and >0.70 high to very high (Hinkle et al.,
1988). This is, however, dependent of the context. For example, a corre-
lation of >0.70 should be expected for instrumentswhile correlations of
a psychosocial nature rarely exceed 0.50 (Polit and Lake, 2010).
2.3.2. Phase I
In line with the hostility analysis of the CATIE and EUFEST studies, a
subset of patients with a baseline PANSS P7 hostility score of at least 2 is
used (i.e. PANSS P7 > 1), since there is no improvement possible in pa-
tients without baseline hostility.
For phase I, raw data were visualized using histograms, and mean
values and SD of differences between baseline values of PANSS-P7/
PSP-D and values at weeks 1, 2 and 4 were summarized in tables.
These differences with their 95% Confidence Intervals (CI) were also vi-
sualized in high-low plots.
A general linearmixedmodel analysis was performed to test the dif-
ferences in scores on PANSS-hostility atweek 1, 2 and 4 (main effect and
interaction with visit). Analyses were controlled for baseline phase I
hostility, baseline phase I PANSS positive items P1-P6 (without hostil-
ity), and visit. Similar analyseswere performed for PSP-D. General linear
mixedmodelswere chosen because these incorporate all availablemea-
surements and can handlemissing values, assuming that these aremiss-
ing at random.
2.3.3. Phase II
For the secondphase, a new selectionwasmadebaseduponhostility
scores at the baseline phase II visit in week 4. For phase II, ITT analyses
were performed. For both randomized groups, data were visualized
using high-low plots, and mean values and SD of differences between
baseline values of PANSS-P7/PSP-D and values at weeks 6, 8 and 10
were summarized in tables.
Again, general linear mixed models were used to test the effect of
randomized treatment (continuation of amisulpride vs. switching to
olanzapine) on PANSS-P7/PSP-D values at week 6, 8 and 10 (main effect
and interaction with visit), controlling for baseline phase II hostility,
baseline phase II PANSS positive items P1-P6 (without hostility) and
visit. SPSS version 25 was used for all analyses.
3. Results
3.1. Sample characteristics
A total of 446 patients comprised the intention-to-treat sample.
Baseline characteristics of this sample are described elsewhere (Kahn
et al., 2018). From these 446 patients, 185 (41.5%) had a baseline
PANSS hostility score > 1 and were included in the hostility subsample.
Of this subsample, most patients had minimal (35.1%) or mild (42.2%)
hostility. A total of 210 patients (47%) of the intention-to-treat sample
scored on the PSP-D at baseline.Manifest,marked, severe or very severe
disturbing or aggressive behaviour was present in 90 (20.2%) patients.
127 patients (28.5%) had both a hostility and PSP-D score. 178 patients
(39.9%) scored on neither of these scales. 58 patients (13%) of the
intention-to-treat sample had a hostility score but no PSP-D. Baseline
characteristics of the hostility subsample are found in Table 1.
Table 1









N (%) N (%) N (%)


















0 (0%) 1 (8.3%)
Education yearsa (mean; SD) 12.1 (3.0) 12.9 (2.4) 10.9 (2.5)
Employment status
Employment or student 74 (40%) 4 (25%) 4 (33.3%)
Unemployed 111
(60%)




5 (31.3) 4 (33.3)






Comorbid major depressive disorder 15 (8.6%) 1 (6.7%) 0 (0%)
Suicidalityc 26
(14.9%)
1 (6.6%) 3 (25%)
Substance abuse or dependence in the past
12 months
40 (23%) 1 (6.7%) 5 (41.7%)
Type of care baseline
Inpatient 114
(61.6%)
9 (56.3%) 4 (33.3%)
Outpatient 71
(38.4%)
7 (43.8%) 8 (66.7%)
Duration of current psychosis, months (mean;
SD)
6.8 (0.47) 9.13 (7.8) 9.8 (7.5)
Antipsychotic naïve at baseline 81
(43.8%)
10 (62%) 9 (75%)
CGI severity (mean; SD) 5.7 (0.9) 5.4 (0.9) 5.7 (0.6)







PANSS positive 23.1 (5.1) 25.2 (6.5) 23.0 (4.4)
PANSS negative 20.7 (6.9) 24.9 (8.1) 22.7 (7.0)






4 (25%) 1 (8.3%)
3- Mild 78
(42.2%)
8 (50%) 5 (41.7%)
4- Moderate 27
(14.6%)
3 (18.8%) 3 (25%)
5- Moderate/severe 9 (4.9%) 0 (0%) 2 (16.7%)
6- Severe 3 (1.6%) 1 (6.3%) 1 (8.3%)
7- Extreme 3 (1.6%) 0 (0%) 0 (0%)
PSP-D
1- Absent 58 (32%) 6 (42.9%) 2 (20%)
2- Mild 61
(33.7%)
7 (50%) 2 (20%)
3- Manifest 33
(18.2%)
0 (0%) 2 (20%)
4- Marked 17 (9.4%) 0 (0%) 2 (20%)
5- Severe 11 (6.1%) 1 (7.1%) 2 (20%)
6- Very severe 1 (0.6%) 0 (0%) 0 (0%)
Data based on sample of patients with baseline hostility >1. PANSS= Positive and Nega-
tive Syndrome Scale; CGI = Clinical Global Impression; PSP-D= Personal and Social Per-
formance Scale domain D: disturbing and aggressive behaviour; AMI = amisulpride;
OLA = olanzapine.
a Years in school from age 6 onwards.
b According to the Mini International Neuropsychiatric Interview 5 plus.
c Suicidality includes medium to high suicide risk.
d Patients with absent hostility at baseline are not included in the hostility subsample.
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3.2. Correlations of PANSS items with hostility (PANSS P7) and disturbing
and aggressive behaviour (PSP-D)
In the intention-to-treat sample, PANSS P7 hostility and PSP-D
disturbing and aggressive behaviour domain are moderate but signifi-
cantly associated with each other (rs = 0.43, p < 0.0005) and with all
other selected PANSS items (Table 2). Hostility has the strongest associ-
ations with poor impulse control (rs = 0.51, p < 0.0005),
uncooperativeness (rs = 0.43, p < 0.0005) and excitement (rs = 0.30,
p < 0.0005). Disturbing and aggressive behaviour is associated with
poor impulse control (rs = 0.50, p < 0.0005) and uncooperativeness
(rs =0.30, p< 0.0005). Gender and duration of psychosis were not sig-
nificantly correlated with hostility.
3.3. Phase I
Themean PANSS P7 hostility score at baseline for the 185 patients in
the hostility subsample was 3.0 (SD = 1.1; Table 3), corresponding to
mild hostility. At week 4, this was 1.8 (SD=1.1) corresponding tomin-
imal or absent hostility. Fig. 1 shows the distribution of the hostility
scores during phase I. At the end of phase I, 10 patients had hostility
scores >3. The mean change in hostility scores from baseline to week
4 is −1.3 (SD = 1.3). The mean PSP-D score at baseline is 2.3 (SD =
1.2) corresponding to mild or manifest disturbing and aggressive be-
haviour and decreased to 1.5 (SD = 0.9) corresponding to absent or
mild disturbing and aggressive behaviour at week 4, a mean change of
−0.8 (SD = 1.2). Fig. 2 displays the mean change for both hostility
and PSP-D.
Primary analysis of phase I hostility controlled for baseline phase I
hostility and baseline phase I PANSS Positive items P1-P6, showed a sig-
nificant reduction over visits (F = 4.111, p = 0.017). Marginal means
were 2.199 (95% CI = 2.040; 2.358) at week 1, 2.119 (95% CI= 1.969;
2.269) at week 2, and 1.933 (95% CI= 1.787; 2.079) at week 4.
3.4. Phase II
A total of 93 patients continued to the second, double blind phase of
the trial. 28 (30.1%) patients had a PANSS P7 hostility score > 1 at the
baseline phase II visit in week 4 and were included in the hostility sub-
sample of phase II. Of these 28 patients, six had a hostility score < 2 at
baseline phase I. 16 patients were randomized to continue with
amisulpride and 12 switched to olanzapine. There are no major differ-
ences in baseline characteristics (Table 1). The mean hostility score at
baseline phase II for patients with amisulpride was 3.1 (SD = 1.0;
Table 4) and for olanzapine this was 3.8 (SD = 1.1). At week 10, this
was 2.5 (SD = 1.2) for patients with amisulpride and 2.3 (SD = 1.6)
for patients with olanzapine. The mean change in phase II was −0.7
(SD=0.8) for patients with amisulpride versus−1.4 (SD=1.4) for pa-
tients with olanzapine (Fig. 2).
Controlled for baseline phase II hostility and baseline phase II PANSS
Positive items P1-P6, primary analysis of the phase II data showed a
trend but no significant reduction in hostility over visits (F = 2.605,
p = 0.087). No significant differences between treatment arms were
found (F = 1.164, p = 0.292).
4. Discussion
The prevalence of moderate, severe and extreme hostility (9.4%)
and manifest, marked, severe or very severe disturbing and aggres-
sive behaviour (20.2%) in this sample of FEP patients is low. As pa-
tients participating in a randomized controlled trial (RCT) are
considered a selected sample, this may not reflect the total popula-
tion of FEP patients. We found PANSS P7 hostility and PSP-D
disturbing and aggressive behaviour low to moderate but signifi-
cantly associated with each other and with PANSS items delusions,
hallucinatory behaviour, tension, unusual thought content and lack
of judgement and insight. The strongest associations, although still
moderate, for both hostility and disturbing and aggressive behaviour
were with poor impulse control, uncooperativeness and excitement.
In the first phase of the trial, amisulpride use was associated with a
reduction in hostile and aggressive behaviour and this association
was still significant after controlling for baseline PANSS positive
symptoms. In the second phase of the trial, we could not demon-
strate a difference between continuation of amisulpride and a switch
to olanzapine.
The prevalence of hostile and aggressive behaviour is the current
sample is lower compared with other studies. In the EUFEST sample,
60.1% of the patients reported baseline hostility >1 compared with
41.5% patients in the current OPTiMiSE sample. The mean hostility
score at baseline in the EUFEST sample was 3.2 (SD = 1.1) versus 3.0
(SD = 1.1) in the OPTiMiSE sample. When comparing these results
with rates of violent behaviour in FEP, it should be mentioned that a
hostility score of 2 is a low threshold to label behaviour as hostile.
PANSS hostility score of 2 indicates “minimal; may be at the upper ex-
treme of normal limits” (Kay et al., 1987). Moderate, severe or extreme
aggression (i.e. PANSS hostility >3) was present in only 42 patients
(9.4%) of the intention-to-treat sample at baseline. This is still lower
than meta-analytic data indicating that around 30% of FEP patients en-
gage in any violence (Large and Nielssen, 2011; Winsper et al., 2013).
There were differences between PANSS and PSP-D scores as only
127 patients (28.5%) scored on both scales. It is expected that pa-
tients score on the PSP but not on the PANSS as the PSP is based on
Table 2
Correlations of selected PANSS items with PANSS P7 hostility and PSP-D.
PANSS items Baseline phase 1
n = 446
PANSS P7 hostility PSP-D
Spearman's rho Spearman's rho
P1 delusions 0.23⁎⁎⁎ 0.23⁎⁎⁎
P3 hallucinatory behaviour 0.13⁎⁎ 0.15⁎⁎
P4 excitement 0.30⁎⁎⁎ 0.27⁎⁎⁎
P7 hostility 1.0 0.43⁎⁎⁎
G4 tension 0.19⁎⁎⁎ 0.11⁎
G8 uncooperativeness 0.43⁎⁎⁎ 0.30⁎⁎⁎
G9 unusual thought content 0.10⁎ 0.19⁎⁎⁎
G12 lack of judgement and insight 0.25⁎⁎⁎ 0.22⁎⁎⁎
G14 poor impulse control 0.51⁎⁎⁎ 0.50⁎⁎⁎
Based on the complete sample of the OPTiMiSE trial at baseline; PANSS = Positive and
Negative Syndrome Scale; PSP-D = Personal and Social Performance Scale domain D:
disturbing and aggressive behaviours.
⁎ P < 0.05.
⁎⁎ P < 0.01.
⁎⁎⁎ P < 0.001.
Table 3
Phase I PANSS P7 hostility and PSP-Dmean scores andmean difference scores for patients
with baseline hostility >1.
Baseline
phase I























PANSS = Positive and Negative Syndrome Scale; PSP-D = Personal and Social Perfor-
mance Scale domainD: disturbing and aggressive behaviour; data based on the subsample
of patients with baseline hostility >1.
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behaviour during the past month and PANSS is aimed at behaviour
during the past week. However, 32% of the hostility subsample did
not score on the PSP-D at baseline. This could be because the
PANSS is more sensitive than the PSP-D and questionable forms of
hostility are not included on the latter.
The results from the correlational analysis are comparable with
previous work. Combined analyses of the CATIE and EUFEST trials
also found hostility associated with positive symptoms and lack of
judgement and insight (Volavka et al., 2016). We confirmed the as-
sociation for impulsivity and hostility with aggressive behaviour in
Fig. 1.Distribution of PANSS P7 hostility scores in patientswith baseline hostility>1during phase I. PANSS=Positive andNegative Syndrome Scale; frequencies of PANSS scores in phase I
of the trial; based on the subsample of patients with baseline hostility >1.
Fig. 2.Mean change of PANSS P7 hostility and PSP-D scores in patients with baseline hostility >1 during phase I and phase II. Data representmean change and 95% CI for the change during
phase 1 (amisulpride) and phase 2 (amisulpride or olanzapine); PANSS= Positive and Negative Syndrome Scale; PSP-D= Personal and Social Performance Scale domain D: disturbing
and aggressive behaviour; based on the subsample of patients with baseline hostility >1.
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FEP (Moulin et al., 2018a, 2018b). Additionally, we found excitement
and uncooperativeness also associated with aggressive behaviour in
a population of FEP. Meta-analytic data from psychotic disorders in
general also found excitement associated with violence, but not
uncooperativeness (Witt et al., 2013). More recent work found
both excitement and uncooperativeness associated with different
aggressiveness outcomes, although with differences between these
measures (Faay and van Os, 2020). Compared with the different re-
sults considering the link between positive symptoms and violent
behaviour in FEP (Brucato et al., 2019; Coid et al., 2013; Langeveld
et al., 2014; Large and Nielssen, 2011) and psychotic disorders in
general, where the positive symptom subscale is associated with vi-
olence (Volavka et al., 2016; Witt et al., 2013), we found hallucina-
tions, delusions and unusual thought content low but significantly
associated with hostility and disturbing and aggressive behaviour.
The reduction in hostility scores in phase I is in line with previous
work. The mean reduction in hostility scores after one month for pa-
tients on amisulpride in the EUFEST study was around−1.2 (Volavka
et al., 2011), which is comparable with our results at week 4 (−1.3).
In both studies, the effect was still significant after controlling for
other positive symptoms.
In the second phase of the trial, we could not find a significant differ-
ence in effect between amisulpride and olanzapine or a significant re-
duction over consecutive visits. This is likely due to the low sample
size and a ceiling effect since the mean scores at baseline phase II are
low and there can only be little improvement. In the EUFEST trial,
olanzapine was significantly superior to amisulpride in reducing hostil-
ity during the first month of treatment (P< 0.05) (Volavka et al., 2011).
The CATIE trial found olanzapine superior to other antipsychotics but
did not use amisulpride (Volavka et al., 2014). A recent meta-analysis
found that amisulpride andolanzapine reduce symptomsof schizophre-
nia to a similar degree (Huhn et al., 2019). Although themechanisms of
the effect of antipsychotics on aggression and hostility are still not fully
understood, aggression is heterogeneous. Not all aggression from pa-
tients with psychotic disorders may be derived from psychosis. There-
fore, efficacy on hostility may change among antipsychotics, not only
because of the general effect of antipsychotics, but also because of differ-
ences in effect on sedation or other symptoms.
The current results have several implications for clinical practice.
First, poor impulse control, excitement and uncooperativeness could
bemore important factors in violent behaviour than positive symptoms.
This could help clinicians in observing and treating these kinds of be-
haviours. Second, these results contribute to the current understanding
of the effect of antipsychotics on aggressive behaviour. Amisulpride is
an effective agent in the treatment of hostile and aggressive patients
and this effect is, at least partly, independent from baseline positive
symptoms, but placebo-controlled studies are needed to confirm this ef-
fect. Moreover, while other studies are aimed at the long term effect of
medications on hostility, the current results are focused on the effect in
the first 10 weeks of treatment after the FEP, where patients are at par-
ticular risk for adverse behaviour, thus providing insight into the clinical
factors and problems in these first weeks of treatment. We believe the
current results imply that amisulpride should be considered for FEP pa-
tients with hostile or aggressive behaviour during the first weeks of
treatment, specifically when olanzapine is contra-indicated because of
the risk for weight-gain.
4.1. Limitations
The current study has several limitations. First, the OPTiMiSE trial
was not designed for an analysis on hostile or aggressive behaviour.
There will probably be some selection bias as patients were able to par-
ticipate in a medication trial and sign an Informed Consent. Coercive
treatment was an exclusion criterion and hostile patients may be
more inclined to refuse study participation. The included patients are
therefore likely to display less aggressive behaviour compared with
FEP patients that are admitted to a hospital on an involuntary basis. Spe-
cifically in phase II, the sample size of the hostility subsample is low and
this may have hampered the comparison between olanzapine and
amisulpride. Second, by using two measures, we provide an indication
of the level of aggressive and hostile behaviour but we do not have in-
formation on aggressive incidents. Incorporation of specific scales that
measure aggression, such as incident report forms, is needed for a
more objective measure of aggressive behaviour. Last, the PSP was not
used according to its guidelines. The PSP is aimed at the behaviour in
the past month but was assessed multiple times within one month,
thus possibly losing subtle changes in patients' behaviour. Also, patients
were selected based on their PANSS P7 hostility score and not on their
PSP-D score.
4.2. Future research
Future research should address differential effects of different anti-
psychotic medication on hostility in FEP, in particular a comparison be-
tween olanzapine and amisulpride may be interesting in a sample of
patients with more severe hostility scores. We hypothesize that
amisulpride and olanzapine are equally effective against hostility during
the first weeks of treatment and that a switch could be effective after a
non-response for several weeks of treatment. This should ideally be
studied with combined outcome measures such as PANSS P7 hostility
and data from incidents reports. Moreover, research should focus on
the effect of different dosages antipsychotics and the use of concomitant
benzodiazepines on aggressive behaviour in FEP. For clinicians, these
are interventions frequently used in order to prevent or treat aggressive
behaviour. Although there is some evidence that higher dosages of anti-
psychotics aremore effective (Faay et al., 2018; Fazel et al., 2014), many
questions about these effects remain. For the effect of benzodiazepines
on aggression or agitation in patients with psychosis there is little
Table 4
Phase II PANSS P7 hostility and PSP-D mean scores and mean difference for patients with baseline phase II hostility >1: amisulpride versus olanzapine.
Baseline phase II Week 6 Week 8 Week 10 Baseline to week 10
PANSS P7 hostility AMI, n = 16
Mean (SD) 3.1 (1.0) 2.6 (1.3) 2.4 (1.3) 2.5 (1.2)
Mean difference (SD) −0.5 (1.1) −0.4 (1.1) 0.1 (0.8) −0.7 (0.8)
OLA, n = 12
Mean (SD) 3.8 (1.1) 3.1 (1.8) 2.2 (1.5) 2.3 (1.6)
Mean difference (SD) −0.7 (1.7) −0.9 (1.1) 0.2 (1.3) −1.4 (1.4)
PSP-D AMI, n = 14
Mean (SD) 1.8 (1.1) 1.9 (1.2) 1.8 (1.3)
Mean difference (SD) 0.1 (0.8) −0.1 (0.8) 0.0 (1.0)
OLA, n = 10
Mean (SD) 3.0 (1.5) 2.1 (1.3) 2.2 (1.5)
Mean difference (SD) −0.8 (1.0) 0.0 (0.5) −0.7 (0.8)
PANSS= Positive and Negative Syndrome Scale; PSP-D= Personal and Social Performance Scale domain D: disturbing and aggressive behaviour; AMI= amisulpride, OLA= olanzapine;
data based on the subsample of patients with baseline hostility >1.
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evidence (Baranchik et al., 2019; Zaman et al., 2018) and the decreased
inhibition benzodiazepines cause might also increase impulsivity and
dangerous behaviour (Guina and Merrill, 2018). As it is difficult to
detangle cause from consequence, this should ideally be studied in a
trial with fixed dosages and regulated benzodiazepine use.
5. Conclusions
The prevalence ofmoderate to severe hostility (9.4%) and disturbing
and aggressive behaviour (20.2%) in this sample of FEP is lowWe found
a significant reduction in PANSS hostility andPSP-D scores after 4weeks
of amisulpride which remained significant after controlling for baseline
positive symptoms, thus indicating that amisulpride could be an effec-
tive antipsychotic choice in the treatment of FEP patients who express
hostile or aggressive behaviour. Future research is needed to compare
the effects of amisulpride and olanzapine on hostility in FEP during
the first weeks of treatment.
Clinical risk factors such as delusions, hallucinatory behaviour, ten-
sion, unusual thought content and lack of judgement and insight could
be important for risk assessment and treatment planning. But the
most meaningful clinical risk factors in detecting and treating hostile
and aggressive behaviour, are poor impulse control, uncooperativeness
and excitement as these symptoms could be observed frompatients' be-
haviour and thereby help clinicians in detecting and treating hostile and
violent behaviour in FEP.
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